Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan, US Agree to Work Together to Develop COVID-19 Treatments: Abe
March 16, 2020
- Japan Enacts State of Emergency Bill over Coronavirus
March 13, 2020
- Japan’s Stance to Look at Overseas Examples for Copay Raises Called into Question
March 13, 2020
- PMDA Prepares “Special Leave” System for Coronavirus Infected Staffers
March 13, 2020
- Annual Drug Price Revisions “Practically Feasible”: Health Policy Advisor
March 12, 2020
- Japan Cabinet OKs Bill to Allow Govt to Declare Emergency over Coronavirus
March 11, 2020
- Japan Govt Orders 20,000 Alvesco Inhalers as Coronavirus Measure
March 11, 2020
- Japan Sets 1st Rollout of Amended PMD Law for Sept. 1
March 9, 2020
- PMDA Reviewing Safety Risks for Xofluza, Keytruda
March 9, 2020
- Japan Starts Health Coverage for COVID-19 Testing
March 6, 2020
- 7 Generic API Specifications Subject to New Rule to Address Unreasonable Price Rises
March 6, 2020
- 3 Drugs Earn Post-Launch “True Clinical Utility” Premium; Forxiga Price Flat, Rises for Canaglu and Praluent
March 5, 2020
- Price Maintenance Premium Granted to 335 APIs/555 Products; Novartis Top PMP Earner
March 5, 2020
- With 80%-Plus Gx Rates, Many One-Time Blockbusters Might Be In for Earlier “G1” Price Cuts
March 5, 2020
- Xolair Faces 37.3% Price Slash, Keytruda 20.9% in April: MHLW
March 5, 2020
- MHLW Orders Package Insert Revisions to Eliminate Vaccination Interval Restriction
March 5, 2020
- Sandostatin Now Eligible for Health Coverage for Congenital Hyperinsulinemia
March 4, 2020
- Japan Mulling Legal Preparations to Declare State of Emergency over Coronavirus
March 4, 2020
- Japan Panel Says No to Nonprescription Switch for Domperidone, Menatetrenone; Decision Now Up for Public Comments
March 3, 2020
- MHLW to Announce New NHI Prices on March 5
March 3, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…